Cargando…

Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia

BACKGROUND: To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy. METHODS: A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYS...

Descripción completa

Detalles Bibliográficos
Autores principales: Alharbi, Norah, Matar, Rawan, Cupler, Edward, Al-Hindi, Hindi, Murad, Hatem, Alhomud, Iftteah, Monies, Dorota, Alshehri, Ali, Alyahya, Mossaed, Meyer, Brian, Bohlega, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902167/
https://www.ncbi.nlm.nih.gov/pubmed/35273475
http://dx.doi.org/10.3389/fnins.2022.815556
_version_ 1784664538412482560
author Alharbi, Norah
Matar, Rawan
Cupler, Edward
Al-Hindi, Hindi
Murad, Hatem
Alhomud, Iftteah
Monies, Dorota
Alshehri, Ali
Alyahya, Mossaed
Meyer, Brian
Bohlega, Saeed
author_facet Alharbi, Norah
Matar, Rawan
Cupler, Edward
Al-Hindi, Hindi
Murad, Hatem
Alhomud, Iftteah
Monies, Dorota
Alshehri, Ali
Alyahya, Mossaed
Meyer, Brian
Bohlega, Saeed
author_sort Alharbi, Norah
collection PubMed
description BACKGROUND: To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy. METHODS: A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYSF) gene was done in a tertiary care referral hospital in Saudi Arabia. Clinical, Neurophysiological, Radiological, Pathological, and Genetic findings in subjects with dysferlin mutation were the primary outcome variables. Statistical analysis was done by Epi-info. RESULTS: 33 out of 112 families (29.46%) registered in the LGMD cohort had Dysferlinopathy. 53 subjects (28 males, 52.83%) from 33 families were followed up for various periods ranging from 1 to 28 years. The mean age of onset was 17.79 ± 3.48 years (Range 10 to 25 years). Miyoshi Myopathy phenotype was observed in 50.94% (27 out of 53), LGMDR2 phenotype in 30.19% (16 out of 53), and proximodistal phenotype in 15.09% (8 out of 53) of the subjects. Loss of ambulation was observed in 39.62% (21 out of 53 subjects). Electrophysiological, Radiological, and histopathological changes were compatible with the diagnosis. Mean serum Creatinine Kinase was 6,464.45 ± 4,149.24 with a range from 302 to 21,483 IU/L. In addition, 13 dysferlin mutations were identified two of them were compound heterozygous. One founder mutation was observed c.164_165insA in 19 unrelated families. CONCLUSION: The prevalence of Dysferlinopathy was 29.46% in the native Saudi LGMD cohort. It is the most prevalent subtype seconded by calpainopathy. The clinical course varied among the study subjects and was consistent with those reported from different ethnic groups. One founder mutation was identified. Initial screening of the founder mutations in new families is highly recommended.
format Online
Article
Text
id pubmed-8902167
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89021672022-03-09 Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia Alharbi, Norah Matar, Rawan Cupler, Edward Al-Hindi, Hindi Murad, Hatem Alhomud, Iftteah Monies, Dorota Alshehri, Ali Alyahya, Mossaed Meyer, Brian Bohlega, Saeed Front Neurosci Neuroscience BACKGROUND: To characterize the phenotypic, neurophysiological, radiological, pathological, and genetic profile of 33 Saudi Arabian families with dysferlinopathy. METHODS: A descriptive observational study was done on a cohort of 112 Saudi Arabian families with LGMD. Screening for the Dysferlin (DYSF) gene was done in a tertiary care referral hospital in Saudi Arabia. Clinical, Neurophysiological, Radiological, Pathological, and Genetic findings in subjects with dysferlin mutation were the primary outcome variables. Statistical analysis was done by Epi-info. RESULTS: 33 out of 112 families (29.46%) registered in the LGMD cohort had Dysferlinopathy. 53 subjects (28 males, 52.83%) from 33 families were followed up for various periods ranging from 1 to 28 years. The mean age of onset was 17.79 ± 3.48 years (Range 10 to 25 years). Miyoshi Myopathy phenotype was observed in 50.94% (27 out of 53), LGMDR2 phenotype in 30.19% (16 out of 53), and proximodistal phenotype in 15.09% (8 out of 53) of the subjects. Loss of ambulation was observed in 39.62% (21 out of 53 subjects). Electrophysiological, Radiological, and histopathological changes were compatible with the diagnosis. Mean serum Creatinine Kinase was 6,464.45 ± 4,149.24 with a range from 302 to 21,483 IU/L. In addition, 13 dysferlin mutations were identified two of them were compound heterozygous. One founder mutation was observed c.164_165insA in 19 unrelated families. CONCLUSION: The prevalence of Dysferlinopathy was 29.46% in the native Saudi LGMD cohort. It is the most prevalent subtype seconded by calpainopathy. The clinical course varied among the study subjects and was consistent with those reported from different ethnic groups. One founder mutation was identified. Initial screening of the founder mutations in new families is highly recommended. Frontiers Media S.A. 2022-02-22 /pmc/articles/PMC8902167/ /pubmed/35273475 http://dx.doi.org/10.3389/fnins.2022.815556 Text en Copyright © 2022 Alharbi, Matar, Cupler, Al-Hindi, Murad, Alhomud, Monies, Alshehri, Alyahya, Meyer and Bohlega. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Alharbi, Norah
Matar, Rawan
Cupler, Edward
Al-Hindi, Hindi
Murad, Hatem
Alhomud, Iftteah
Monies, Dorota
Alshehri, Ali
Alyahya, Mossaed
Meyer, Brian
Bohlega, Saeed
Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia
title Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia
title_full Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia
title_fullStr Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia
title_full_unstemmed Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia
title_short Clinical, Neurophysiological, Radiological, Pathological, and Genetic Features of Dysferlinopathy in Saudi Arabia
title_sort clinical, neurophysiological, radiological, pathological, and genetic features of dysferlinopathy in saudi arabia
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902167/
https://www.ncbi.nlm.nih.gov/pubmed/35273475
http://dx.doi.org/10.3389/fnins.2022.815556
work_keys_str_mv AT alharbinorah clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT matarrawan clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT cupleredward clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT alhindihindi clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT muradhatem clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT alhomudiftteah clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT moniesdorota clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT alshehriali clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT alyahyamossaed clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT meyerbrian clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia
AT bohlegasaeed clinicalneurophysiologicalradiologicalpathologicalandgeneticfeaturesofdysferlinopathyinsaudiarabia